Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Non-Current Assets: 2015-2025

Historic Non-Current Assets for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Sep 2025 value amounting to $22.0 million.

  • Syndax Pharmaceuticals' Non-Current Assets rose 99.62% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year increase of 99.62%. This contributed to the annual value of $121.8 million for FY2024, which is 280.45% up from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Non-Current Assets stood at $22.0 million for Q3 2025, which was down 65.94% from $64.5 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' 5-year Non-Current Assets high stood at $121.8 million for Q4 2024, and its period low was $504,000 during Q2 2021.
  • Moreover, its 3-year median value for Non-Current Assets was $30.9 million (2024), whereas its average is $47.5 million.
  • In the last 5 years, Syndax Pharmaceuticals' Non-Current Assets soared by 2,707.54% in 2022 and then plummeted by 39.72% in 2024.
  • Syndax Pharmaceuticals' Non-Current Assets (Quarterly) stood at $1.3 million in 2021, then surged by 490.80% to $7.5 million in 2022, then spiked by 329.58% to $32.0 million in 2023, then soared by 280.45% to $121.8 million in 2024, then soared by 99.62% to $22.0 million in 2025.
  • Its last three reported values are $22.0 million in Q3 2025, $64.5 million for Q2 2025, and $92.0 million during Q1 2025.